Moreover, B68 can reduce the expression of PD‐L1 on the surface of senescent cells by targeting CSN5, thereby blocking the direct interaction between PD‐1 on T cells and PD‐L1 on tumor cells, activating the immune microenvironment within the tumor, increasing the number of effective CD8+ T cells, reducing the number of MSDCs and Treg cells, and effectively eliminating senescent tumor cells. Here, CD8A is linked to neoplasm.